GlaxoSmithKline PLC at Citi BioPharma Conference (Virtual) Transcript
Very good afternoon. Delighted that you could join the GSK ViiV session. My name is Andrew Baum. I'm delighted to be joined by Dr. Kimberly Smith, the Head of R&D at ViiV. Thank you so much for joining us today. We've also got Frannie DeFranco from GSK's IR on the call with us. So look, we've got about 45 minutes to talk to what is really a critical part of GSK's business, not just in the fact it's serving an important unmet need but from a contribution economically. Because of the very high contribution margin, it punches well above the weight of the just near revenue contribution. So it's one that merits a lot of focus.
Questions & Answers
Now perhaps to kick off, if I was to set out a devil's advocate view of the landscape that this is a field where previous dominant franchises have been eclipsed by competitors and have ceded control of the space, and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
